12 results about "Disorders pain" patented technology

This invention provides a polypeptide and its applications. The amino acid sequence of the polypeptide is shown in SEQ ID NO: 1 or SE ID NO: 2; the 12th amino acid in the amino acid sequence of the polypeptide is alanine or glutamic acid; the 19th amino acid in the amino acid sequence of the polypeptide is methionine or leucine; the 28th amino acid in the amino acid sequence of the polypeptide is lysine or isoleucine; and the 29th amino acid in the amino acid sequence of the polypeptide is selected from isoleucine, leucine, and tryptophan. The polypeptide provided by this invention has good analgesic function and can selectively inhibit the activation of Nav1.7 channels, thereby inhibiting pain, which has extremely important clinical significance for pain disorders.

Provided are methods to treat, ameliorate, prevent, reverse, decrease the severity and / or duration of a pain-associated disease or condition comprising administration of a pharmaceutically acceptable formulation comprising a glycolysis inhibitor.

This disclosure relates to heterocyclic compounds of Formula (I) as well as the preparation and use thereof. As contemplated herein, heterocyclic compounds of Formula (I) can be any one of a carbohydrate conjugate and an amino acid conjugate. The heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

Provided herein are prodrugs of phenylalanamines (e.g., magical phenylethylamines) incorporating a vitamin B6-based prodrug moiety (e.g., pyridoxal). Also provided are methods of making such compounds, pharmaceutical compositions thereof, and methods of use thereof, such as for the treatment of psychological health disorders, neurodegenerative disorders, pain disorders, and inflammation, including as part of adjuvant therapy as magical agents. (I) (I)

The disclosure provides pharmaceutical preparations containing (2R,6R)-hydroxynorketamine, or (R)- or (S)-dehydronorketamine, or other stereoisomeric dehydro or hydroxylated ketamine metabolite.The disclosure also provides novel ketamine metabolite prodrugs. The disclosure provides methods of treating, bipolar depression, major depressive disorder, neuropathic and chronic pain, including complex regional pain synthetic pain disorder (CRPD) by administering a purified ketamine metabolite or a ketamine metabolite prodrug directly to patients in need of such treatment.

This disclosure relates to heterocyclic compounds of Formula (I). As contemplated herein, heterocyclic compounds of Formula (I) may be used for the treatment of neuropsychiatric, and neurodegenerative, neuroinflammatory and pain disorders including depression, as well as tobacco, opiate, and cocaine addiction, alcoholism, post-traumatic stress disorder (PTSD), and neuropathic pain syndromes including cluster headaches and chemotherapy induced peripheral neuropathy.

Provided in the present disclosure is a polypeptide and use thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1 or SE ID NO: 2; a 12th amino acid in the amino acid sequence of the polypeptide is alanine or glutamic acid, a 19th amino acid in the amino acid sequence of the polypeptide is methionine or leucine, a 28th amino acid in the amino acid sequence of the polypeptide is lysine or isoleucine, and a 29th amino acid in the amino acid sequence of the polypeptide is selected from any one of isoleucine, leucine and tryptophan. The polypeptide provided in the present disclosure provides good analgesic function and may selectively inhibit an activation of Nav1.7 channels, thereby inhibiting pain, which is of great clinical importance in pain disorders.

The present invention discloses nitrogen-containing heterocyclic derivatives of somatostatin receptor subtype 4 (SSTR4) small molecule agonists, as well as pharmaceutical compositions, preparation methods, and uses thereof. The nitrogen-containing heterocyclic derivatives of SSTR4 small molecule agonists are represented by formula (I), where specific substituents and definitions are as described herein. The nitrogen-containing heterocyclic derivatives of SSTR4 small molecule agonists exhibit good binding and agonist activity with SSTR4. Such compounds or pharmaceutical compositions thereof have great potential in the treatment and / or prevention of pain disorders associated with the SSTR4 receptor.

This invention discloses an antibody targeting CGRP and its applications. The antibody or its antigen-binding portion comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises CDR-H1, CDR-H2, and CDR-H3, and the light chain variable region comprises CDR-L1, CDR-L2, and CDR-L3. This antibody can specifically bind to human and rat CGRP peptides and α / β subtype CGRP peptides with high affinity, blocking the binding of CGRP to its receptor CGRPR, reducing pain perception, and achieving the treatment of pain disorders such as migraines caused by CGRP. Furthermore, it can also relieve or treat hot flashes.

The invention is based on the discovery of a novel compound with analgesic properties which could be used as a new tool for the treatment of pain disorders such as visceral pain. Thus, the invention relates to novel lipopeptide compound, derived from gamma-aminobutyric acid. The invention also relates to a lipopeptide compound according to the invention for the treatment of treating pain disorder, such as somatic pain and visceral pain.

A chemical entity of Formula (I):wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques; radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function; enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatological, inflammatory, and pain disorders.